Blended Survival Curves: A New Approach to Extrapolation for Time-to-Event Outcomes from Clinical Trial in Health Technology Assessment

06/01/2022
by   Zhaojing Che, et al.
0

Background Survival extrapolation is essential in the cost-effectiveness analysis to quantify the lifetime survival benefit associated with a new intervention, due to the restricted duration of randomized controlled trials (RCTs). Current approaches of extrapolation often assume that the treatment effect observed in the trial can continue indefinitely, which is unrealistic and may have a huge impact on decisions for resource allocation. Objective We introduce a novel methodology as a possible solution to alleviate the problem of performing survival extrapolation with heavily censored data from clinical trials. Method The main idea is to mix a flexible model (e.g., Cox semi-parametric) to fit as well as possible the observed data and a parametric model encoding assumptions on the expected behaviour of underlying long-term survival. The two are "blended" into a single survival curve that is identical with the Cox model over the range of observed times and gradually approaching the parametric model over the extrapolation period based on a weight function. The weight function regulates the way two survival curves are blended, determining how the internal and external sources contribute to the estimated survival over time. Results A 4-year follow-up RCT of rituximab in combination with fludarabine and cyclophosphamide v. fludarabine and cyclophosphamide alone for the first-line treatment of chronic lymphocytic leukemia is used to illustrate the method. Conclusion Long-term extrapolation from immature trial data may lead to significantly different estimates with various modelling assumptions. The blending approach provides sufficient flexibility, allowing a wide range of plausible scenarios to be considered as well as the inclusion of genuine external information, based e.g. on hard data or expert opinion. Both internal and external validity can be carefully examined.

READ FULL TEXT

page 1

page 2

page 3

page 4

research
10/24/2019

The use of registry data to extrapolate overall survival results from randomised controlled trials

Background: Pre-marketing authorisation estimates of survival are genera...
research
06/06/2023

survextrap: a package for flexible and transparent survival extrapolation

Health policy decisions are often informed by estimates of long-term sur...
research
08/19/2019

Bayesian models for survival data of clinical trials: Comparison of implementations using R software

Objective: To provide guidance for the use of the main functions availab...
research
01/31/2021

Nonparametric Analysis of Delayed Treatment Effects using Single-Crossing Constraints

Clinical trials involving novel immuno-oncology (IO) therapies frequentl...
research
03/18/2022

A Comparison of Different Methods to Adjust Survival Curves for Confounders

Treatment specific survival curves are an important tool to illustrate t...
research
12/04/2021

Utilizing Expert Opinion to inform Extrapolation of Survival Models

In decision modelling with time to event data, there are a variety of pa...
research
06/10/2022

Quantification of follow-up time in oncology clinical trials with a time-to-event endpoint: Asking the right questions

For the analysis of a time-to-event endpoint in a single-arm or randomiz...

Please sign up or login with your details

Forgot password? Click here to reset